ANRO
Alto Neuroscience Inc.

1,100
Mkt Cap
$380.16M
Volume
390,575.00
52W High
$15.04
52W Low
$1.60
PE Ratio
-5.85
ANRO Fundamentals
Price
$14.21
Prev Close
$14.04
Open
$13.81
50D MA
$5.62
Beta
1.67
Avg. Volume
79,206.71
EPS (Annual)
-$2.50
P/B
3.08
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Alto Neuroscience to Participate in Upcoming Investor Conferences
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that...
Business Wire·2d ago
News Placeholder
More News
News Placeholder
Here's Why Alto Neuroscience, Inc. (ANRO) is a Great Momentum Stock to Buy
Does Alto Neuroscience, Inc. (ANRO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·7d ago
News Placeholder
Can Alto Neuroscience, Inc. (ANRO) Climb 27.45% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 27.5% upside potential for Alto Neuroscience, Inc. (ANRO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·7d ago
News Placeholder
Alto Neuroscience Stock Soars After FDA Grants Fast Track Designation To Schizophrenia Drug
FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.
Stocktwits·27d ago
News Placeholder
Alto Neuroscience, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ANRO
Alto Neuroscience, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ANRO Alto Neuroscience, Inc. Sued for Securities Law Violations...
PR Newswire·3mo ago
News Placeholder
1 ‘Strong Buy’ Penny Stock With 270% Upside to Load Up On in March
Alto Neuroscience represents a high-risk, high-reward opportunity.
barchart.com·8mo ago
News Placeholder
Alto Neuroscience Is Down Nearly 35% This Year, But Retail Traders Keep Flocking To Micro-Cap Stock
While ALTO-100's Phase 2 results failed to meet expectations, the company has emphasized the potential of ALTO-300, another MDD treatment currently in Phase 2b trials.
Stocktwits·8mo ago
News Placeholder
Alto Neuroscience to Participate in Upcoming Investor Conferences
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that...
Business Wire·8mo ago
News Placeholder
Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that the...
Business Wire·8mo ago
News Placeholder
Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced multiple...
Business Wire·11mo ago

Latest ANRO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.